SlideShare une entreprise Scribd logo
1  sur  33
RAGHAV DOGRA
M .PHARMA(PHARMACEUTICAL ANALYSIS)
2ND SEMESTER
Assay of Adsorbed Diptheria Vaccine
and Adsorbed Tetanus Vaccine
TABLE OF CONTENT
 INTRODUCTION TO ADV.
 PRINCIPLE OF ASSAY.
 LETHAL CHALLENGE METHOD.
 INTRODUCTION TO ATV.
 PRINCIPLE OF ASSAY.
 ASSAY METHOD OF ATV.
 METHOD A. CHALLENGE TOXN IN GUINEA PIG.
 METHOD B. CHALLENGE TOXIN IN MICE.
 METHOD C. DETERMINATION OF ANTIBODIES IN GUINEA PIG
 GUIDELINES
INTRODUCTION OF ADV:
 Adsorbed Diphtheria Vaccine (ADV) is an anti-toxin
preparation containing antitoxic globulins that have
the power of specifically neutralizing the toxin
formed by Corynebacterium diphtheria.
 It is obtained by fraction of horse or other mammal
serum, that have been immunized against
Diphtheria toxin.
 Diphtheria vaccine is generally available in the
combination with the Tetanus And Pertusis vaccine
or DPT.
 The formal Toxoid is prepared from the toxin
Cont…
 It is generally prepared by combining Diphtheria
formal toxoid with mineral carrier i.e. hydrated
Aluminum hydroxide, Ammonium hydroxide or
Phosphates ,Calcium Phosphates etc.
Diphtheria formal
Toxoid
Mineral Carrier such
as Aluminum,
Ammonium Hydroxide
etc
Adsorbed Diphtheria Toxin(
ADV)
PRINCIPLE OF ASSAY:
 The potency of Diphtheria antitoxin is
determined by comparing the dose necessary
to protect the guinea pig or rabbit against the
erythrogenic effect of a fixed dose of the
standard preparation of Diphtheria toxin
required necessary to give same protection.
SELECTION OF CHALLENGE TOXIN:
 Selection of the challenge toxin is based upon reacting
dose (Lr).
 The preparation containing 67-133 Lr/mL in Lime
flocculation's (lf) of Diphtheria Toxin (DT) is selected or
the preparation with 25000 to 50000 minimal reacting
doses for guinea pig skin in 1lf.
 The toxin are stored in the refrigeration 0-5˚C and
Toluene is added as antimicrobial preservatives which
does not cause rapid decline in toxicity.
PREPARATION OF STANDARD TOXIN:
 It is prepared in a saline solution having 1mL of
preparation having 0.1 IU of toxin followed by:
 1mL of standard preparation along with 0.2 IU test
toxin.
 1mL of standard preparation along with 0.3IU test
toxin.
 Store the preparation away from light.
PREPARATION OF CHALLENGE
TOXIN:
 Challenge toxin / preparation to be assayed is diluted
with phosphate buffer solution (PBS) of pH 7.4.
 The challenge toxin solution is diluted in the same
solution upto the following level:
 2LD50
 LD50
 ½LD50
LETHAL CHALLENGE METHOD:
 Test animal such as guinea Pig, Horses, Rabbits are
selected for this.
 If guinea pig then it should be of 250-350 gm.
 The animal are grouped into 6 groups of 16 animals
each having same sex.
 0.2 mL of each mixture should be injected
subcutaneously or intradermally into the animal.
 The animals are observed after 48 hours for specific
Diphtheria erythema.
 Mixture containing larger amount of toxin will give
severe reaction and vice versa.
DETERMINATION OF POTENCY OF
THE VACCINE:
 The 3 dilutions of sample and standard vaccine are
prepared in saline solution.
 Inject into guinea pigs.
 This should protect 50% animals from lethal effect of
subcutaneous injection.
 Calculate the potency of the vaccine relative to the
potency of potency of standard preparation on the
basis of the number of animals survived in each
VALIDITY OF TEST:
 Vaccine under examination and standard
preparation , the 50% protective doses lies between
the largest and the smallest dose of the preparation
given to guinea pigs.
 Mortality increases when increases in toxin dose
level is there the minimum amount of toxin which
when combined should cause a local skin reaction
that is just visible and indicates the presence of
toxin.
INTRODUCTION TO ATV:
 Tetanus vaccine, also known as tetanus toxoid (TT), is
an inactive vaccine used to prevent tetanus.
 During childhood five doses are recommended, followed by
additional doses every ten years. After three doses almost
everyone is immune. In those who are not up to date on
their tetanus immunization a booster should be given within
48 hours of an injury.
 In those with high risk injuries who are not fully immunized
tetanus antitoxin may also be recommended. Making sure
women who are pregnant are up to date on their tetanus
immunization and, if not, immunizing them can
prevent neonatal tetanus.
Contd..
 Tetanus Toxoid Adsorbed USP, for intramuscular use, is
a sterile suspension of alum-precipitated (aluminum
potassium sulfate) toxoid in an
isotonic sodium chloride solution containing
sodium phosphate buffer to control pH.
 Clostridium tetani culture is grown in a peptone-based
medium and detoxified with formaldehyde. The detoxified
material is then purified by serial ammonium sulfate
fractionation, followed by sterile filtration, and the toxoid is
adsorbed to aluminum potassium sulfate (alum). The
adsorbed toxoid is diluted with physiological saline solution
0.85%.
 Each 0.5 mL dose is formulated to contain 5 Lf
PRINCIPLE:
• The potency of tetanus vaccine is determined by
administration of the vaccine to animals i.e. guinea-pigs or
mice followed administration of either challenge with
tetanus toxin or by determining of the titre of antibodies
against tetanus Toxoid in the serum of the guinea-pigs.
• In both cases the potency of the vaccine is calculated by
comparison with a reference vaccine, calibrated in
International Units.
 Tetanus vaccine (adsorbed) BRP is calibrated in
International Units with reference to the International
Standard.
ASSAY METHODS OF ATV:
ASSAY OF ADSORBED
TETANUS VACCINE
METHOD B. CHALLENGE
TEST IN MICE.
METHOD A. CHALLENGE
TEST IN GUINEA-PIGS.
METHOD C. DETERMINATION OF
ANTIBODIES IN
GUINEA-PIGS
METHOD A.CHALLENGE TOXIN IN
GUINEA PIG
 SELECTION AND DISTRIBUTION OF TEST ANIMALS:
 Healthy guinea pigs from the same stock should be selected of
weight 250-350 gm.
 Animals are distributed in not less than 6 equal groups
containing no. of animals sufficient to obtain results
 If the validity of the challenge toxin is to be determined 3 further
groups of the 5 animals each should be taken which are used
as unvaccinated control.
 Animals should be of same sex if both sex are included then the
Contd…
 SELECTION OF CHALLENGE TOXIN:
 Preparation of tetanus toxin containing not less than 50
times the 50 per cent paralytic dose per millilitre is
selected.
 If the challenge toxin preparation has been shown to be
stable, it is not necessary to verify the paralytic dose for
every assay.
PREPARATION OF CHALLENGE TOXIN SOLUTION:
 The challenge toxin is immediately diluted to 50 times the
50 per cent paralytic dose per millilitre with the, peptone
buffered saline solution pH 7.4 etc to obtain stable
challenge toxin.
 DILUTION OF THE TEST AND REFERENCE
SOLUTION:
 The vaccine to be examined and the reference preparation
are diluted with the 9g/l solution of NaCl.
 The dilution forms series which do not differ the by 2.5
folds from the alternating previous and next dilutions.
 When injected subcutaneously with dose of 1.0 mL per
guinea pig should protect approximately 50% of animals
from the paralytic effects of tetanus toxin prescribed for
test.
 IMMUNIZATION CHALLENGE AND CHALLENGE:
 Allocate the dilutions to the groups.
 Then Inject subcutaneously 1 mL allocated dilution into the
Contd..
Contd…
 DETERMINATION OF ACTIVITY OF THE CHALLENGE
TOXIN:
 3 dilutions made from the challenge toxin and each dilution
were allocated to 1 group of 5 guinea pigs i.e. 3 groups if
necessary.
 Subcutaneously inject 1mL of allocated solution into each
guinea pig of the group.
 The activity and stability of the challenge toxin are
determined by carrying out a suitable number of
determinations of the 50 per cent paralytic dose.
Contd..
 READING AND INTERPRETATION OF RESULTS:
 The guinea-pigs are examined twice daily. Remove and
humanely kill all animals showing definite signs of tetanus
paralysis.
 The number of guinea-pigs without paralysis 5 days after
injection of the challenge toxin are counted.
 Calculate the potency of the vaccine to be examined
relative to the potency of the reference preparation on the
basis of the proportion of challenged animals without
paralysis in each of the groups of vaccinated guinea-pigs,
using the usual statistical methods
Contd..
 REQUIREMENTS FOR A VALID ASSAY:
 The test is not valid unless, for both the vaccine to be
examined and the reference preparation the 50 per cent
protective dose lies between the largest and smallest
doses of the preparations given to the guinea-pigs,
 if applicable, the number of paralyzed animals in the 3
groups of 5 injected with the dilutions of the challenge toxin
solution indicates that the challenge was approximately 50
times the 50 per cent paralytic dose,
 the confidence limits (P = 0.95) are not less than 50 per
cent and not more than 200 per cent of the estimated
potency,
 the statistical analysis shows significant slope and no
deviation from linearity and parallelism of the dose
METHOD B.CHALLENGE TOXIN IN MICE:
 SELECTION AND DISTRIBUTION OF TEST ANIMALS:
 Use in the test healthy mice from the same stock, about 5
weeks old and from a strain shown to be suitable. Rest
same as guinea pig.
 SELECTION OF CHALLENGE TOXIN:
 Preparation of tetanus toxin containing not less than 100
times the 50 per cent paralytic dose per millilitre is
selected.
 PREPARATION OF CHALLENGE TOXIN SOLUTION:
 DILUTION OF THE TEST AND REFERENCE
SOLUTION:
 IMMUNIZATION CHALLENGE AND CHALLENGE:
 DETERMINATION OF ACTIVITY OF THE CHALLENGE
Contd..
 READING AND INTERPRETATION OF RESULTS:
 The mice are examined twice daily. Remove and humanely
kill all animals showing definite signs of tetanus paralysis.
 The number of mice without paralysis 4 days after injection
of the challenge toxin are counted.
 Calculate the potency of the vaccine to be examined
relative to the potency of the reference preparation on the
basis of the proportion of challenged animals without
paralysis in each of the groups of vaccinated guinea-pigs,
using the usual statistical methods.
METHOD C. DETERMINATION OF
ANTBODIES IN GUINEA PIG
 SELECTION AND DISTRIBUTION OF TEST ANIMALS:
 Healthy guinea pigs from the same stock should be selected of
weight 250-350 gm.
 Animals are distributed in not less than 6 equal groups
containing no. of animals sufficient to obtain results.
 Animals should be of same sex if both sex are included then the
should be equally distributed among groups.
 Use a further group of non-vaccinated guinea-pigs of the same
origin to provide a negative serum control. If test consistency
has been demonstrated, a reference negative serum control
may be used.
Contd…
 REFERENCE PREPARATION:
 A suitable reference preparation such as tetanus
vaccine(adsorbed) BRP or a batch of vaccine shown to be
effective in clinical studies, or a batch representative thereof,
and which has been calibrated in International Units with
reference to tetanus vaccine (adsorbed) BRP or the
International Standard for tetanus toxoid (adsorbed) are used.
 DILUTION OF THE TEST AND REFERENCE SOLUTION:
 The vaccine to be examined and the reference preparation are
diluted with the 9g/l solution of NaCl.
 The dilution forms series which do not differ the by 2.5 to 5 folds
from the alternating previous and next dilutions. Use not fewer
than 3 dilutions within the range for example 0.5-16 IU/ml for
each series. Use dilutions for immunization preferably within 1 h
of preparation. Allocate 1 dilution to each group of guinea-pigs.
Contd…
 IMMUNISATION:
 Inject subcutaneously in the nape of each guinea-pig 1.0
ml of the dilution allocated to its group.
 BLOOD SAMPLING:
 35-42 days after immunization, take a blood sample from
each vaccinated and control guinea-pig using a suitable
method.
 PREPARATION OF SERUM SAMPLES:
 Avoid frequent freezing and thawing of serum samples. To
avoid microbial contamination, it is preferable to carry out
manipulations in a laminar-flow cabinet.
Contd…
 DETERMINATION OF ANTIBODY TITRE:
 Determine the relative antibody titre or score of each
serum sample by a suitable immunochemical method . The
methods shown below (enzyme-linked immunosorbent
assay (ELISA) and toxin-binding inhibition (ToBI)) have
been found suitable.
 CALCULATION OF POTENCY:
 Calculate the potency of the vaccine to be examined in
International Units relative to the reference preparation,
using the usual statistical methods (for example 5.3).
 NOTE: International Units of potency refer to the
reference vaccine and not to the International Units of
Contd…
 Requirements for a valid assay. The test is not valid
unless :
 The confidence limits (P = 0.95) are not less than 50
percent and not more than 200 per cent of the estimated
potency,
 The statistical analysis shows significant slope and no
deviation from linearity and parallelism of the dose-
response lines .
 The test may be repeated but when more than 1 test is
performed the results of all valid tests must be combined in
the estimate of potency.
GUIDELINES…
 READING AND INTERPRETATION OF RESULTS:
 In order to minimize suffering in the test animals, it is
recommended to note the degree of paralysis on a
scale such as that shown below. The scale gives
typical signs when injection of the challenge toxin is
made mid-ventrally directly behind the sternum with
the needle pointing towards the neck of the guinea-pig
mice and . Grade T3 is taken as the end-point, but with
experience grade T2 can be used instead. Tetanus
toxin produces in at least 1 of the forelimbs paralysis
that can be recognized at an early stage. The tetanus
grades in guinea-pigs and mice are characterized by
Contd..
 T1: slight stiffness of 1 forelimb, but difficult to observe
 T2: paresis of 1 forelimb which still can function.
 T3: paralysis of 1 forelimb. The animal moves reluctantly,
the body is often slightly banana-shaped owing to scoliosis
;
 T4: the forelimb is completely stiff and the toes are
immovable. The muscular contraction of the forelimb is
very pronounced and usually scoliosis is observed;
 T5: tetanus seizures, continuous tonic spasm of muscles ;
 D:death.
Contd…
 METHOD C. DETERMINATION OF ANTIBODIES IN
GUINEA-PIGS
 PREPARATION OF SERUM SAMPLES:
 For preparation of serum samples, the following technique
has been found suitable. Invert the tubes containing blood
samples 6 times and allow to stand at 37 °C for 2 h, then at
4 °C for 2 h. Centrifuge at room temperature at 800 g for
20 min. Transfer the serum to sterile tubes and store at a
temperature below −20 °C. At least 40 per cent yield of
serum is obtained by this procedure.
 DETERMINATION OF ANTIBODY TITRE:
 The ELISA and ToBI tests shown below are given as
examples of immunochemical methods that have been
found suitable for the determination of antibody titre.
Assay of adsorbed diptheria vaccine and adsorbed tetanus

Contenu connexe

Tendances

Biological test and assay of Absorbed Diphtheria vaccine
Biological test and assay of  Absorbed Diphtheria vaccineBiological test and assay of  Absorbed Diphtheria vaccine
Biological test and assay of Absorbed Diphtheria vaccineUshaKhanal3
 
IMPURITIES AND STABILITY STUDIES
IMPURITIES AND STABILITY STUDIESIMPURITIES AND STABILITY STUDIES
IMPURITIES AND STABILITY STUDIESprakash64742
 
Impurity profiling and degradent characterization {presented by shameer m.pha...
Impurity profiling and degradent characterization {presented by shameer m.pha...Impurity profiling and degradent characterization {presented by shameer m.pha...
Impurity profiling and degradent characterization {presented by shameer m.pha...ShameerAbid
 
ANALYSIS OF FERMENTATION PRODUCTS BY HIMAJA
ANALYSIS OF FERMENTATION PRODUCTS BY HIMAJAANALYSIS OF FERMENTATION PRODUCTS BY HIMAJA
ANALYSIS OF FERMENTATION PRODUCTS BY HIMAJAhimaja donthula
 
IMPURITIES OF NEW DRUG PRODUCTS
IMPURITIES OF NEW DRUG PRODUCTS IMPURITIES OF NEW DRUG PRODUCTS
IMPURITIES OF NEW DRUG PRODUCTS prakash64742
 
Impurities in residual solvents
Impurities in residual solventsImpurities in residual solvents
Impurities in residual solventsMehulJain143
 
Rationale for the reporting control of degradation products
Rationale for the reporting control of degradation products Rationale for the reporting control of degradation products
Rationale for the reporting control of degradation products ManiKandan1405
 
Bioassay of Heparin Sodium
Bioassay of Heparin SodiumBioassay of Heparin Sodium
Bioassay of Heparin SodiumSathiyaThaarani
 
POTENTIAL SOURCES OF ELEMENTAL IMPURITIES
POTENTIAL SOURCES OF ELEMENTAL IMPURITIESPOTENTIAL SOURCES OF ELEMENTAL IMPURITIES
POTENTIAL SOURCES OF ELEMENTAL IMPURITIESMehulJain143
 
elemental classification & control of elemental impurities.pptx
elemental classification & control of elemental impurities.pptxelemental classification & control of elemental impurities.pptx
elemental classification & control of elemental impurities.pptxAvneeshMishra33
 
Ich guidelines for stability testing of biotechnological biological products (1)
Ich guidelines for stability testing of biotechnological biological products (1)Ich guidelines for stability testing of biotechnological biological products (1)
Ich guidelines for stability testing of biotechnological biological products (1)Dr Raj kumar Kudari
 
Validation of pharaceutical water system and pure steam
Validation of pharaceutical water system and pure steamValidation of pharaceutical water system and pure steam
Validation of pharaceutical water system and pure steamJp Prakash
 

Tendances (20)

Adsorbed Diphtheria Vaccine.
Adsorbed Diphtheria Vaccine.Adsorbed Diphtheria Vaccine.
Adsorbed Diphtheria Vaccine.
 
Biological test and assay of Absorbed Diphtheria vaccine
Biological test and assay of  Absorbed Diphtheria vaccineBiological test and assay of  Absorbed Diphtheria vaccine
Biological test and assay of Absorbed Diphtheria vaccine
 
IMPURITIES AND STABILITY STUDIES
IMPURITIES AND STABILITY STUDIESIMPURITIES AND STABILITY STUDIES
IMPURITIES AND STABILITY STUDIES
 
Impurity profiling and degradent characterization {presented by shameer m.pha...
Impurity profiling and degradent characterization {presented by shameer m.pha...Impurity profiling and degradent characterization {presented by shameer m.pha...
Impurity profiling and degradent characterization {presented by shameer m.pha...
 
BIOASSAY OF TETANUS ANTITOXIN
BIOASSAY OF TETANUS ANTITOXINBIOASSAY OF TETANUS ANTITOXIN
BIOASSAY OF TETANUS ANTITOXIN
 
ANALYSIS OF FERMENTATION PRODUCTS BY HIMAJA
ANALYSIS OF FERMENTATION PRODUCTS BY HIMAJAANALYSIS OF FERMENTATION PRODUCTS BY HIMAJA
ANALYSIS OF FERMENTATION PRODUCTS BY HIMAJA
 
IMPURITIES OF NEW DRUG PRODUCTS
IMPURITIES OF NEW DRUG PRODUCTS IMPURITIES OF NEW DRUG PRODUCTS
IMPURITIES OF NEW DRUG PRODUCTS
 
Impurities in residual solvents
Impurities in residual solventsImpurities in residual solvents
Impurities in residual solvents
 
Assays of rabies vaccine
Assays of rabies vaccineAssays of rabies vaccine
Assays of rabies vaccine
 
Residual solvents as impurities
Residual solvents as impuritiesResidual solvents as impurities
Residual solvents as impurities
 
Rationale for the reporting control of degradation products
Rationale for the reporting control of degradation products Rationale for the reporting control of degradation products
Rationale for the reporting control of degradation products
 
Bioassay of TT antitoxin
Bioassay of TT antitoxinBioassay of TT antitoxin
Bioassay of TT antitoxin
 
Bioassay of Heparin Sodium
Bioassay of Heparin SodiumBioassay of Heparin Sodium
Bioassay of Heparin Sodium
 
High Performance Thin Layer Chromatography (HPTLC) Fingerprinting
High Performance Thin Layer Chromatography (HPTLC) FingerprintingHigh Performance Thin Layer Chromatography (HPTLC) Fingerprinting
High Performance Thin Layer Chromatography (HPTLC) Fingerprinting
 
POTENTIAL SOURCES OF ELEMENTAL IMPURITIES
POTENTIAL SOURCES OF ELEMENTAL IMPURITIESPOTENTIAL SOURCES OF ELEMENTAL IMPURITIES
POTENTIAL SOURCES OF ELEMENTAL IMPURITIES
 
Qualification of Gas Chromatography
Qualification of Gas Chromatography Qualification of Gas Chromatography
Qualification of Gas Chromatography
 
elemental classification & control of elemental impurities.pptx
elemental classification & control of elemental impurities.pptxelemental classification & control of elemental impurities.pptx
elemental classification & control of elemental impurities.pptx
 
Ich guidelines for stability testing of biotechnological biological products (1)
Ich guidelines for stability testing of biotechnological biological products (1)Ich guidelines for stability testing of biotechnological biological products (1)
Ich guidelines for stability testing of biotechnological biological products (1)
 
Methods of Detection of Natural, Permitted and Non Permitted Dyes
Methods of Detection of Natural, Permitted and Non Permitted DyesMethods of Detection of Natural, Permitted and Non Permitted Dyes
Methods of Detection of Natural, Permitted and Non Permitted Dyes
 
Validation of pharaceutical water system and pure steam
Validation of pharaceutical water system and pure steamValidation of pharaceutical water system and pure steam
Validation of pharaceutical water system and pure steam
 

En vedette

Class vaccines and sera
Class vaccines and sera Class vaccines and sera
Class vaccines and sera Raghu Prasada
 
Chem 45 Biochemistry: Stoker chapter 24 Carbohydrate Metabolism
Chem 45 Biochemistry: Stoker chapter 24 Carbohydrate MetabolismChem 45 Biochemistry: Stoker chapter 24 Carbohydrate Metabolism
Chem 45 Biochemistry: Stoker chapter 24 Carbohydrate MetabolismShaina Mavreen Villaroza
 
Carbohydrate Metabolism - Biochemistry
Carbohydrate Metabolism - BiochemistryCarbohydrate Metabolism - Biochemistry
Carbohydrate Metabolism - BiochemistryCU Dentistry 2019
 
Carbohydrate metabolism
Carbohydrate metabolismCarbohydrate metabolism
Carbohydrate metabolismHaseeb Quadri
 

En vedette (6)

Class vaccines and sera
Class vaccines and sera Class vaccines and sera
Class vaccines and sera
 
Microbiological assay of vaccines
Microbiological assay of vaccinesMicrobiological assay of vaccines
Microbiological assay of vaccines
 
Chem 45 Biochemistry: Stoker chapter 24 Carbohydrate Metabolism
Chem 45 Biochemistry: Stoker chapter 24 Carbohydrate MetabolismChem 45 Biochemistry: Stoker chapter 24 Carbohydrate Metabolism
Chem 45 Biochemistry: Stoker chapter 24 Carbohydrate Metabolism
 
Carbohydrate Metabolism - Biochemistry
Carbohydrate Metabolism - BiochemistryCarbohydrate Metabolism - Biochemistry
Carbohydrate Metabolism - Biochemistry
 
Carbohydrate metabolism
Carbohydrate metabolismCarbohydrate metabolism
Carbohydrate metabolism
 
Carbohydrate metabolism
Carbohydrate metabolismCarbohydrate metabolism
Carbohydrate metabolism
 

Similaire à Assay of adsorbed diptheria vaccine and adsorbed tetanus

Micro biological assay of vaccines
Micro biological assay of vaccinesMicro biological assay of vaccines
Micro biological assay of vaccinessiva ganesh
 
BIOASSAY OF TITANUS ANTI TIOXIN AND DIPTHERIA VACCINE
BIOASSAY OF TITANUS ANTI TIOXIN AND DIPTHERIA VACCINEBIOASSAY OF TITANUS ANTI TIOXIN AND DIPTHERIA VACCINE
BIOASSAY OF TITANUS ANTI TIOXIN AND DIPTHERIA VACCINEprakash64742
 
Bio assay of adsorbed diptheria vaccines
Bio assay of adsorbed diptheria vaccinesBio assay of adsorbed diptheria vaccines
Bio assay of adsorbed diptheria vaccinesSkAzizuddin1
 
Rabies vaccine ppt by royal
Rabies vaccine ppt by royalRabies vaccine ppt by royal
Rabies vaccine ppt by royalhusnatazeen
 
SCREENING OF immuno.pptx
SCREENING OF immuno.pptxSCREENING OF immuno.pptx
SCREENING OF immuno.pptxSourinDe2
 
Invivo screening methods for anti inflammatory agents
Invivo screening methods for anti inflammatory  agentsInvivo screening methods for anti inflammatory  agents
Invivo screening methods for anti inflammatory agentsSravani Ganti
 
Antimicrobial therapies in reproduction
Antimicrobial therapies in reproductionAntimicrobial therapies in reproduction
Antimicrobial therapies in reproductionDr. Ishwor Dhakal
 
rabies vaccine and tetanus anti serum FOR PHARM ANALYSIS
 rabies vaccine and tetanus anti serum FOR PHARM ANALYSIS rabies vaccine and tetanus anti serum FOR PHARM ANALYSIS
rabies vaccine and tetanus anti serum FOR PHARM ANALYSISprakash64742
 
Pre clinical evaluation of pertussis vaccine (1)
Pre clinical evaluation of pertussis vaccine (1)Pre clinical evaluation of pertussis vaccine (1)
Pre clinical evaluation of pertussis vaccine (1)indus university-icri
 
ABHISHEK S2 APA ANTI- VENOM advanced pharmaceutical analysis
ABHISHEK S2 APA ANTI- VENOM advanced pharmaceutical analysisABHISHEK S2 APA ANTI- VENOM advanced pharmaceutical analysis
ABHISHEK S2 APA ANTI- VENOM advanced pharmaceutical analysisVenkatesan R - 6369851191
 
Inprocess quality control tests for biological products
Inprocess quality control tests for biological productsInprocess quality control tests for biological products
Inprocess quality control tests for biological productsnishathfathima
 
BIOLIFE JOURNAL 2 4 2014
BIOLIFE JOURNAL 2 4 2014BIOLIFE JOURNAL 2 4 2014
BIOLIFE JOURNAL 2 4 2014Estari Mamidala
 

Similaire à Assay of adsorbed diptheria vaccine and adsorbed tetanus (20)

Micro biological assay of vaccines
Micro biological assay of vaccinesMicro biological assay of vaccines
Micro biological assay of vaccines
 
BIOASSAY OF TITANUS ANTI TIOXIN AND DIPTHERIA VACCINE
BIOASSAY OF TITANUS ANTI TIOXIN AND DIPTHERIA VACCINEBIOASSAY OF TITANUS ANTI TIOXIN AND DIPTHERIA VACCINE
BIOASSAY OF TITANUS ANTI TIOXIN AND DIPTHERIA VACCINE
 
Bio assay of adsorbed diptheria vaccines
Bio assay of adsorbed diptheria vaccinesBio assay of adsorbed diptheria vaccines
Bio assay of adsorbed diptheria vaccines
 
Rabies vaccine ppt by royal
Rabies vaccine ppt by royalRabies vaccine ppt by royal
Rabies vaccine ppt by royal
 
Tuberculin purified protein derivative
Tuberculin purified protein derivativeTuberculin purified protein derivative
Tuberculin purified protein derivative
 
SCREENING OF immuno.pptx
SCREENING OF immuno.pptxSCREENING OF immuno.pptx
SCREENING OF immuno.pptx
 
Diphtheria vaccine
Diphtheria vaccineDiphtheria vaccine
Diphtheria vaccine
 
FMDV
FMDVFMDV
FMDV
 
Invivo screening methods for anti inflammatory agents
Invivo screening methods for anti inflammatory  agentsInvivo screening methods for anti inflammatory  agents
Invivo screening methods for anti inflammatory agents
 
Rabies Vaccine
Rabies VaccineRabies Vaccine
Rabies Vaccine
 
Antimicrobial therapies in reproduction
Antimicrobial therapies in reproductionAntimicrobial therapies in reproduction
Antimicrobial therapies in reproduction
 
S2 KAVANA BB APA-TETANUS ANTITOXIN.pptx
S2 KAVANA BB  APA-TETANUS ANTITOXIN.pptxS2 KAVANA BB  APA-TETANUS ANTITOXIN.pptx
S2 KAVANA BB APA-TETANUS ANTITOXIN.pptx
 
rabies vaccine and tetanus anti serum FOR PHARM ANALYSIS
 rabies vaccine and tetanus anti serum FOR PHARM ANALYSIS rabies vaccine and tetanus anti serum FOR PHARM ANALYSIS
rabies vaccine and tetanus anti serum FOR PHARM ANALYSIS
 
Pre clinical evaluation of pertussis vaccine (1)
Pre clinical evaluation of pertussis vaccine (1)Pre clinical evaluation of pertussis vaccine (1)
Pre clinical evaluation of pertussis vaccine (1)
 
ABHISHEK S2 APA ANTI- VENOM advanced pharmaceutical analysis
ABHISHEK S2 APA ANTI- VENOM advanced pharmaceutical analysisABHISHEK S2 APA ANTI- VENOM advanced pharmaceutical analysis
ABHISHEK S2 APA ANTI- VENOM advanced pharmaceutical analysis
 
Anti-inflammatory Activity of Sting Protein from Apis mellifera
Anti-inflammatory Activity of Sting Protein from Apis melliferaAnti-inflammatory Activity of Sting Protein from Apis mellifera
Anti-inflammatory Activity of Sting Protein from Apis mellifera
 
Inprocess quality control tests for biological products
Inprocess quality control tests for biological productsInprocess quality control tests for biological products
Inprocess quality control tests for biological products
 
Ascoli test
Ascoli testAscoli test
Ascoli test
 
BIOLIFE JOURNAL 2 4 2014
BIOLIFE JOURNAL 2 4 2014BIOLIFE JOURNAL 2 4 2014
BIOLIFE JOURNAL 2 4 2014
 
polyvac 50
polyvac 50polyvac 50
polyvac 50
 

Plus de RAGHAV DOGRA

Regulatory requirement for setting herbal drug industry
Regulatory requirement for setting herbal drug industryRegulatory requirement for setting herbal drug industry
Regulatory requirement for setting herbal drug industryRAGHAV DOGRA
 
some Monograph of herbal drugs according to siddha and unani pharmacopoeia
 some Monograph of herbal drugs according to siddha and unani pharmacopoeia some Monograph of herbal drugs according to siddha and unani pharmacopoeia
some Monograph of herbal drugs according to siddha and unani pharmacopoeiaRAGHAV DOGRA
 
Pharmaceutical inspection convention
Pharmaceutical inspection conventionPharmaceutical inspection convention
Pharmaceutical inspection conventionRAGHAV DOGRA
 
Columchromatography rv
Columchromatography rvColumchromatography rv
Columchromatography rvRAGHAV DOGRA
 

Plus de RAGHAV DOGRA (8)

Regulatory requirement for setting herbal drug industry
Regulatory requirement for setting herbal drug industryRegulatory requirement for setting herbal drug industry
Regulatory requirement for setting herbal drug industry
 
some Monograph of herbal drugs according to siddha and unani pharmacopoeia
 some Monograph of herbal drugs according to siddha and unani pharmacopoeia some Monograph of herbal drugs according to siddha and unani pharmacopoeia
some Monograph of herbal drugs according to siddha and unani pharmacopoeia
 
Pharmaceutical inspection convention
Pharmaceutical inspection conventionPharmaceutical inspection convention
Pharmaceutical inspection convention
 
Dyslexia
DyslexiaDyslexia
Dyslexia
 
Mass spectrometry
Mass spectrometryMass spectrometry
Mass spectrometry
 
Drug interactions
Drug interactionsDrug interactions
Drug interactions
 
Flame phtometry
Flame phtometryFlame phtometry
Flame phtometry
 
Columchromatography rv
Columchromatography rvColumchromatography rv
Columchromatography rv
 

Dernier

Nutritional Needs Presentation - HLTH 104
Nutritional Needs Presentation - HLTH 104Nutritional Needs Presentation - HLTH 104
Nutritional Needs Presentation - HLTH 104misteraugie
 
Class 11th Physics NEET formula sheet pdf
Class 11th Physics NEET formula sheet pdfClass 11th Physics NEET formula sheet pdf
Class 11th Physics NEET formula sheet pdfAyushMahapatra5
 
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptx
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptxSOCIAL AND HISTORICAL CONTEXT - LFTVD.pptx
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptxiammrhaywood
 
Application orientated numerical on hev.ppt
Application orientated numerical on hev.pptApplication orientated numerical on hev.ppt
Application orientated numerical on hev.pptRamjanShidvankar
 
Measures of Central Tendency: Mean, Median and Mode
Measures of Central Tendency: Mean, Median and ModeMeasures of Central Tendency: Mean, Median and Mode
Measures of Central Tendency: Mean, Median and ModeThiyagu K
 
Grant Readiness 101 TechSoup and Remy Consulting
Grant Readiness 101 TechSoup and Remy ConsultingGrant Readiness 101 TechSoup and Remy Consulting
Grant Readiness 101 TechSoup and Remy ConsultingTechSoup
 
microwave assisted reaction. General introduction
microwave assisted reaction. General introductionmicrowave assisted reaction. General introduction
microwave assisted reaction. General introductionMaksud Ahmed
 
Unit-IV- Pharma. Marketing Channels.pptx
Unit-IV- Pharma. Marketing Channels.pptxUnit-IV- Pharma. Marketing Channels.pptx
Unit-IV- Pharma. Marketing Channels.pptxVishalSingh1417
 
Accessible design: Minimum effort, maximum impact
Accessible design: Minimum effort, maximum impactAccessible design: Minimum effort, maximum impact
Accessible design: Minimum effort, maximum impactdawncurless
 
Sports & Fitness Value Added Course FY..
Sports & Fitness Value Added Course FY..Sports & Fitness Value Added Course FY..
Sports & Fitness Value Added Course FY..Disha Kariya
 
How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17Celine George
 
Unit-V; Pricing (Pharma Marketing Management).pptx
Unit-V; Pricing (Pharma Marketing Management).pptxUnit-V; Pricing (Pharma Marketing Management).pptx
Unit-V; Pricing (Pharma Marketing Management).pptxVishalSingh1417
 
PROCESS RECORDING FORMAT.docx
PROCESS      RECORDING        FORMAT.docxPROCESS      RECORDING        FORMAT.docx
PROCESS RECORDING FORMAT.docxPoojaSen20
 
Introduction to Nonprofit Accounting: The Basics
Introduction to Nonprofit Accounting: The BasicsIntroduction to Nonprofit Accounting: The Basics
Introduction to Nonprofit Accounting: The BasicsTechSoup
 
Holdier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdfHoldier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdfagholdier
 
The basics of sentences session 2pptx copy.pptx
The basics of sentences session 2pptx copy.pptxThe basics of sentences session 2pptx copy.pptx
The basics of sentences session 2pptx copy.pptxheathfieldcps1
 

Dernier (20)

Mehran University Newsletter Vol-X, Issue-I, 2024
Mehran University Newsletter Vol-X, Issue-I, 2024Mehran University Newsletter Vol-X, Issue-I, 2024
Mehran University Newsletter Vol-X, Issue-I, 2024
 
Nutritional Needs Presentation - HLTH 104
Nutritional Needs Presentation - HLTH 104Nutritional Needs Presentation - HLTH 104
Nutritional Needs Presentation - HLTH 104
 
Class 11th Physics NEET formula sheet pdf
Class 11th Physics NEET formula sheet pdfClass 11th Physics NEET formula sheet pdf
Class 11th Physics NEET formula sheet pdf
 
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptx
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptxSOCIAL AND HISTORICAL CONTEXT - LFTVD.pptx
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptx
 
Application orientated numerical on hev.ppt
Application orientated numerical on hev.pptApplication orientated numerical on hev.ppt
Application orientated numerical on hev.ppt
 
Measures of Central Tendency: Mean, Median and Mode
Measures of Central Tendency: Mean, Median and ModeMeasures of Central Tendency: Mean, Median and Mode
Measures of Central Tendency: Mean, Median and Mode
 
Grant Readiness 101 TechSoup and Remy Consulting
Grant Readiness 101 TechSoup and Remy ConsultingGrant Readiness 101 TechSoup and Remy Consulting
Grant Readiness 101 TechSoup and Remy Consulting
 
microwave assisted reaction. General introduction
microwave assisted reaction. General introductionmicrowave assisted reaction. General introduction
microwave assisted reaction. General introduction
 
INDIA QUIZ 2024 RLAC DELHI UNIVERSITY.pptx
INDIA QUIZ 2024 RLAC DELHI UNIVERSITY.pptxINDIA QUIZ 2024 RLAC DELHI UNIVERSITY.pptx
INDIA QUIZ 2024 RLAC DELHI UNIVERSITY.pptx
 
Unit-IV- Pharma. Marketing Channels.pptx
Unit-IV- Pharma. Marketing Channels.pptxUnit-IV- Pharma. Marketing Channels.pptx
Unit-IV- Pharma. Marketing Channels.pptx
 
Accessible design: Minimum effort, maximum impact
Accessible design: Minimum effort, maximum impactAccessible design: Minimum effort, maximum impact
Accessible design: Minimum effort, maximum impact
 
Sports & Fitness Value Added Course FY..
Sports & Fitness Value Added Course FY..Sports & Fitness Value Added Course FY..
Sports & Fitness Value Added Course FY..
 
Código Creativo y Arte de Software | Unidad 1
Código Creativo y Arte de Software | Unidad 1Código Creativo y Arte de Software | Unidad 1
Código Creativo y Arte de Software | Unidad 1
 
How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17
 
Unit-V; Pricing (Pharma Marketing Management).pptx
Unit-V; Pricing (Pharma Marketing Management).pptxUnit-V; Pricing (Pharma Marketing Management).pptx
Unit-V; Pricing (Pharma Marketing Management).pptx
 
Advance Mobile Application Development class 07
Advance Mobile Application Development class 07Advance Mobile Application Development class 07
Advance Mobile Application Development class 07
 
PROCESS RECORDING FORMAT.docx
PROCESS      RECORDING        FORMAT.docxPROCESS      RECORDING        FORMAT.docx
PROCESS RECORDING FORMAT.docx
 
Introduction to Nonprofit Accounting: The Basics
Introduction to Nonprofit Accounting: The BasicsIntroduction to Nonprofit Accounting: The Basics
Introduction to Nonprofit Accounting: The Basics
 
Holdier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdfHoldier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdf
 
The basics of sentences session 2pptx copy.pptx
The basics of sentences session 2pptx copy.pptxThe basics of sentences session 2pptx copy.pptx
The basics of sentences session 2pptx copy.pptx
 

Assay of adsorbed diptheria vaccine and adsorbed tetanus

  • 1. RAGHAV DOGRA M .PHARMA(PHARMACEUTICAL ANALYSIS) 2ND SEMESTER Assay of Adsorbed Diptheria Vaccine and Adsorbed Tetanus Vaccine
  • 2. TABLE OF CONTENT  INTRODUCTION TO ADV.  PRINCIPLE OF ASSAY.  LETHAL CHALLENGE METHOD.  INTRODUCTION TO ATV.  PRINCIPLE OF ASSAY.  ASSAY METHOD OF ATV.  METHOD A. CHALLENGE TOXN IN GUINEA PIG.  METHOD B. CHALLENGE TOXIN IN MICE.  METHOD C. DETERMINATION OF ANTIBODIES IN GUINEA PIG  GUIDELINES
  • 3. INTRODUCTION OF ADV:  Adsorbed Diphtheria Vaccine (ADV) is an anti-toxin preparation containing antitoxic globulins that have the power of specifically neutralizing the toxin formed by Corynebacterium diphtheria.  It is obtained by fraction of horse or other mammal serum, that have been immunized against Diphtheria toxin.  Diphtheria vaccine is generally available in the combination with the Tetanus And Pertusis vaccine or DPT.  The formal Toxoid is prepared from the toxin
  • 4. Cont…  It is generally prepared by combining Diphtheria formal toxoid with mineral carrier i.e. hydrated Aluminum hydroxide, Ammonium hydroxide or Phosphates ,Calcium Phosphates etc. Diphtheria formal Toxoid Mineral Carrier such as Aluminum, Ammonium Hydroxide etc Adsorbed Diphtheria Toxin( ADV)
  • 5.
  • 6. PRINCIPLE OF ASSAY:  The potency of Diphtheria antitoxin is determined by comparing the dose necessary to protect the guinea pig or rabbit against the erythrogenic effect of a fixed dose of the standard preparation of Diphtheria toxin required necessary to give same protection.
  • 7. SELECTION OF CHALLENGE TOXIN:  Selection of the challenge toxin is based upon reacting dose (Lr).  The preparation containing 67-133 Lr/mL in Lime flocculation's (lf) of Diphtheria Toxin (DT) is selected or the preparation with 25000 to 50000 minimal reacting doses for guinea pig skin in 1lf.  The toxin are stored in the refrigeration 0-5˚C and Toluene is added as antimicrobial preservatives which does not cause rapid decline in toxicity.
  • 8. PREPARATION OF STANDARD TOXIN:  It is prepared in a saline solution having 1mL of preparation having 0.1 IU of toxin followed by:  1mL of standard preparation along with 0.2 IU test toxin.  1mL of standard preparation along with 0.3IU test toxin.  Store the preparation away from light.
  • 9. PREPARATION OF CHALLENGE TOXIN:  Challenge toxin / preparation to be assayed is diluted with phosphate buffer solution (PBS) of pH 7.4.  The challenge toxin solution is diluted in the same solution upto the following level:  2LD50  LD50  ½LD50
  • 10. LETHAL CHALLENGE METHOD:  Test animal such as guinea Pig, Horses, Rabbits are selected for this.  If guinea pig then it should be of 250-350 gm.  The animal are grouped into 6 groups of 16 animals each having same sex.  0.2 mL of each mixture should be injected subcutaneously or intradermally into the animal.  The animals are observed after 48 hours for specific Diphtheria erythema.  Mixture containing larger amount of toxin will give severe reaction and vice versa.
  • 11. DETERMINATION OF POTENCY OF THE VACCINE:  The 3 dilutions of sample and standard vaccine are prepared in saline solution.  Inject into guinea pigs.  This should protect 50% animals from lethal effect of subcutaneous injection.  Calculate the potency of the vaccine relative to the potency of potency of standard preparation on the basis of the number of animals survived in each
  • 12. VALIDITY OF TEST:  Vaccine under examination and standard preparation , the 50% protective doses lies between the largest and the smallest dose of the preparation given to guinea pigs.  Mortality increases when increases in toxin dose level is there the minimum amount of toxin which when combined should cause a local skin reaction that is just visible and indicates the presence of toxin.
  • 13. INTRODUCTION TO ATV:  Tetanus vaccine, also known as tetanus toxoid (TT), is an inactive vaccine used to prevent tetanus.  During childhood five doses are recommended, followed by additional doses every ten years. After three doses almost everyone is immune. In those who are not up to date on their tetanus immunization a booster should be given within 48 hours of an injury.  In those with high risk injuries who are not fully immunized tetanus antitoxin may also be recommended. Making sure women who are pregnant are up to date on their tetanus immunization and, if not, immunizing them can prevent neonatal tetanus.
  • 14. Contd..  Tetanus Toxoid Adsorbed USP, for intramuscular use, is a sterile suspension of alum-precipitated (aluminum potassium sulfate) toxoid in an isotonic sodium chloride solution containing sodium phosphate buffer to control pH.  Clostridium tetani culture is grown in a peptone-based medium and detoxified with formaldehyde. The detoxified material is then purified by serial ammonium sulfate fractionation, followed by sterile filtration, and the toxoid is adsorbed to aluminum potassium sulfate (alum). The adsorbed toxoid is diluted with physiological saline solution 0.85%.  Each 0.5 mL dose is formulated to contain 5 Lf
  • 15. PRINCIPLE: • The potency of tetanus vaccine is determined by administration of the vaccine to animals i.e. guinea-pigs or mice followed administration of either challenge with tetanus toxin or by determining of the titre of antibodies against tetanus Toxoid in the serum of the guinea-pigs. • In both cases the potency of the vaccine is calculated by comparison with a reference vaccine, calibrated in International Units.  Tetanus vaccine (adsorbed) BRP is calibrated in International Units with reference to the International Standard.
  • 16. ASSAY METHODS OF ATV: ASSAY OF ADSORBED TETANUS VACCINE METHOD B. CHALLENGE TEST IN MICE. METHOD A. CHALLENGE TEST IN GUINEA-PIGS. METHOD C. DETERMINATION OF ANTIBODIES IN GUINEA-PIGS
  • 17. METHOD A.CHALLENGE TOXIN IN GUINEA PIG  SELECTION AND DISTRIBUTION OF TEST ANIMALS:  Healthy guinea pigs from the same stock should be selected of weight 250-350 gm.  Animals are distributed in not less than 6 equal groups containing no. of animals sufficient to obtain results  If the validity of the challenge toxin is to be determined 3 further groups of the 5 animals each should be taken which are used as unvaccinated control.  Animals should be of same sex if both sex are included then the
  • 18. Contd…  SELECTION OF CHALLENGE TOXIN:  Preparation of tetanus toxin containing not less than 50 times the 50 per cent paralytic dose per millilitre is selected.  If the challenge toxin preparation has been shown to be stable, it is not necessary to verify the paralytic dose for every assay. PREPARATION OF CHALLENGE TOXIN SOLUTION:  The challenge toxin is immediately diluted to 50 times the 50 per cent paralytic dose per millilitre with the, peptone buffered saline solution pH 7.4 etc to obtain stable challenge toxin.
  • 19.  DILUTION OF THE TEST AND REFERENCE SOLUTION:  The vaccine to be examined and the reference preparation are diluted with the 9g/l solution of NaCl.  The dilution forms series which do not differ the by 2.5 folds from the alternating previous and next dilutions.  When injected subcutaneously with dose of 1.0 mL per guinea pig should protect approximately 50% of animals from the paralytic effects of tetanus toxin prescribed for test.  IMMUNIZATION CHALLENGE AND CHALLENGE:  Allocate the dilutions to the groups.  Then Inject subcutaneously 1 mL allocated dilution into the Contd..
  • 20. Contd…  DETERMINATION OF ACTIVITY OF THE CHALLENGE TOXIN:  3 dilutions made from the challenge toxin and each dilution were allocated to 1 group of 5 guinea pigs i.e. 3 groups if necessary.  Subcutaneously inject 1mL of allocated solution into each guinea pig of the group.  The activity and stability of the challenge toxin are determined by carrying out a suitable number of determinations of the 50 per cent paralytic dose.
  • 21. Contd..  READING AND INTERPRETATION OF RESULTS:  The guinea-pigs are examined twice daily. Remove and humanely kill all animals showing definite signs of tetanus paralysis.  The number of guinea-pigs without paralysis 5 days after injection of the challenge toxin are counted.  Calculate the potency of the vaccine to be examined relative to the potency of the reference preparation on the basis of the proportion of challenged animals without paralysis in each of the groups of vaccinated guinea-pigs, using the usual statistical methods
  • 22. Contd..  REQUIREMENTS FOR A VALID ASSAY:  The test is not valid unless, for both the vaccine to be examined and the reference preparation the 50 per cent protective dose lies between the largest and smallest doses of the preparations given to the guinea-pigs,  if applicable, the number of paralyzed animals in the 3 groups of 5 injected with the dilutions of the challenge toxin solution indicates that the challenge was approximately 50 times the 50 per cent paralytic dose,  the confidence limits (P = 0.95) are not less than 50 per cent and not more than 200 per cent of the estimated potency,  the statistical analysis shows significant slope and no deviation from linearity and parallelism of the dose
  • 23. METHOD B.CHALLENGE TOXIN IN MICE:  SELECTION AND DISTRIBUTION OF TEST ANIMALS:  Use in the test healthy mice from the same stock, about 5 weeks old and from a strain shown to be suitable. Rest same as guinea pig.  SELECTION OF CHALLENGE TOXIN:  Preparation of tetanus toxin containing not less than 100 times the 50 per cent paralytic dose per millilitre is selected.  PREPARATION OF CHALLENGE TOXIN SOLUTION:  DILUTION OF THE TEST AND REFERENCE SOLUTION:  IMMUNIZATION CHALLENGE AND CHALLENGE:  DETERMINATION OF ACTIVITY OF THE CHALLENGE
  • 24. Contd..  READING AND INTERPRETATION OF RESULTS:  The mice are examined twice daily. Remove and humanely kill all animals showing definite signs of tetanus paralysis.  The number of mice without paralysis 4 days after injection of the challenge toxin are counted.  Calculate the potency of the vaccine to be examined relative to the potency of the reference preparation on the basis of the proportion of challenged animals without paralysis in each of the groups of vaccinated guinea-pigs, using the usual statistical methods.
  • 25. METHOD C. DETERMINATION OF ANTBODIES IN GUINEA PIG  SELECTION AND DISTRIBUTION OF TEST ANIMALS:  Healthy guinea pigs from the same stock should be selected of weight 250-350 gm.  Animals are distributed in not less than 6 equal groups containing no. of animals sufficient to obtain results.  Animals should be of same sex if both sex are included then the should be equally distributed among groups.  Use a further group of non-vaccinated guinea-pigs of the same origin to provide a negative serum control. If test consistency has been demonstrated, a reference negative serum control may be used.
  • 26. Contd…  REFERENCE PREPARATION:  A suitable reference preparation such as tetanus vaccine(adsorbed) BRP or a batch of vaccine shown to be effective in clinical studies, or a batch representative thereof, and which has been calibrated in International Units with reference to tetanus vaccine (adsorbed) BRP or the International Standard for tetanus toxoid (adsorbed) are used.  DILUTION OF THE TEST AND REFERENCE SOLUTION:  The vaccine to be examined and the reference preparation are diluted with the 9g/l solution of NaCl.  The dilution forms series which do not differ the by 2.5 to 5 folds from the alternating previous and next dilutions. Use not fewer than 3 dilutions within the range for example 0.5-16 IU/ml for each series. Use dilutions for immunization preferably within 1 h of preparation. Allocate 1 dilution to each group of guinea-pigs.
  • 27. Contd…  IMMUNISATION:  Inject subcutaneously in the nape of each guinea-pig 1.0 ml of the dilution allocated to its group.  BLOOD SAMPLING:  35-42 days after immunization, take a blood sample from each vaccinated and control guinea-pig using a suitable method.  PREPARATION OF SERUM SAMPLES:  Avoid frequent freezing and thawing of serum samples. To avoid microbial contamination, it is preferable to carry out manipulations in a laminar-flow cabinet.
  • 28. Contd…  DETERMINATION OF ANTIBODY TITRE:  Determine the relative antibody titre or score of each serum sample by a suitable immunochemical method . The methods shown below (enzyme-linked immunosorbent assay (ELISA) and toxin-binding inhibition (ToBI)) have been found suitable.  CALCULATION OF POTENCY:  Calculate the potency of the vaccine to be examined in International Units relative to the reference preparation, using the usual statistical methods (for example 5.3).  NOTE: International Units of potency refer to the reference vaccine and not to the International Units of
  • 29. Contd…  Requirements for a valid assay. The test is not valid unless :  The confidence limits (P = 0.95) are not less than 50 percent and not more than 200 per cent of the estimated potency,  The statistical analysis shows significant slope and no deviation from linearity and parallelism of the dose- response lines .  The test may be repeated but when more than 1 test is performed the results of all valid tests must be combined in the estimate of potency.
  • 30. GUIDELINES…  READING AND INTERPRETATION OF RESULTS:  In order to minimize suffering in the test animals, it is recommended to note the degree of paralysis on a scale such as that shown below. The scale gives typical signs when injection of the challenge toxin is made mid-ventrally directly behind the sternum with the needle pointing towards the neck of the guinea-pig mice and . Grade T3 is taken as the end-point, but with experience grade T2 can be used instead. Tetanus toxin produces in at least 1 of the forelimbs paralysis that can be recognized at an early stage. The tetanus grades in guinea-pigs and mice are characterized by
  • 31. Contd..  T1: slight stiffness of 1 forelimb, but difficult to observe  T2: paresis of 1 forelimb which still can function.  T3: paralysis of 1 forelimb. The animal moves reluctantly, the body is often slightly banana-shaped owing to scoliosis ;  T4: the forelimb is completely stiff and the toes are immovable. The muscular contraction of the forelimb is very pronounced and usually scoliosis is observed;  T5: tetanus seizures, continuous tonic spasm of muscles ;  D:death.
  • 32. Contd…  METHOD C. DETERMINATION OF ANTIBODIES IN GUINEA-PIGS  PREPARATION OF SERUM SAMPLES:  For preparation of serum samples, the following technique has been found suitable. Invert the tubes containing blood samples 6 times and allow to stand at 37 °C for 2 h, then at 4 °C for 2 h. Centrifuge at room temperature at 800 g for 20 min. Transfer the serum to sterile tubes and store at a temperature below −20 °C. At least 40 per cent yield of serum is obtained by this procedure.  DETERMINATION OF ANTIBODY TITRE:  The ELISA and ToBI tests shown below are given as examples of immunochemical methods that have been found suitable for the determination of antibody titre.